Context:

FDA vaccine chief Vinay Prasad is leaving the agency for a second time, with an end-of-April departure and a return to his UCSF faculty post. A controversial figure, he has been at the center of debates over vaccine and specialty drug reviews, balancing efforts to speed approvals with new warnings and study requirements. The episode follows a prior July ouster and rapid reinstatement backed by Health Secretary Kennedy and FDA Commissioner Makary, highlighting a fraught regulatory environment and partisan pressure around vaccines and biotech therapies. The development underscores ongoing leadership tensions and questions about regulatory reform, with Prasad's exit signaling a return to academia as the agency navigates policy direction. The outlook suggests continued turbulence in vaccine regulation and an emphasis on balancing speed with safety in the post-epidemic era.

Dive Deeper:

• Prasad’s departure marks the second exit from the FDA within a year, with the latest ending planned for the end of April and a return to his academic role at the University of California, San Francisco.

• In July, he was briefly ousted after clashes with biotech executives, patient groups, and Trump‑aligned allies, but was reinstated less than two weeks later with backing from Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Makary.

• His tenure has been defined by a dual stance: pushing faster, easier drug reviews for industry while also imposing new warnings and study requirements for certain biotech vaccines and therapies, notably those connected to COVID-19.

• Kennedy, who shifted from anti-vaccine advocacy to supporting regulatory changes, has been a recurring figure linked to Prasad’s regulatory approach, contributing to the politically charged environment around vaccine reviews.

• Makary announced the news to FDA staff via email, framing the move as Prasad’s return to academia and underscoring a broader pattern of contentious review decisions within the agency.